Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast)

Abstract

Introduction: Atazanavir is a protease inhibitor recently introduce in the therapeutic arsenal for second-line antiretroviral therapy in Ivory Coast. The objective of this study was to compare the efficacy and safety of a second-line treatment with 2 NRTIs + boosted lopinavir (LPV/r) versus 2 NRTIs + boosted atazanavir (ATV/r) in HIV-1 positive patients in Abidjan. Patients and Methods: Retrospective, comparative, single-center study, in 194 HIV-1 positive patients (143 with LPV/r, 51 with ATV/r), failed a first-line treatment, followed in Abidjan on 1 May 2009 to 30 June 2010. The analysis focused on clinical parameters and immuno-virological data. The principal judgement criterion was the proportion of patients with undetectable viral load in both groups after 12 months of HAART. Tolerance was found on the frequency of adverse events grade 3-4 during follow-up. Results: Clinically, improvement of the general condition and regression of opportunistic infections was similar in both groups. The average gain of CD4 after 12 months of follow-up was +357/mm3 in the LPV/r group versus +278 mm3 for ATV/r group (p = 0.012). The percentage of patients with undetectable viral load was similar in both groups (92% vs. 96% ; p = 0.535). The frequency of grade 3-4 adverse events was similar in both groups. Conclusion: HAART with LPV/r is at least as efficient as with ATV/r in second-line treatment, in terms of viral load reduction, with better recovery of CD4. LPV/r is an excellent second-line treatment in resource-limited countries. J Microbiol Infect Dis 2016;6(4): 149-155  Abidjan, Atazanavir, HIV, Lopinavir, Second-line, Sub-Saharan Africa

Keywords

• Abidjan,Atazanavir,HIV,Lopinavir,Second-line,Sub-Saharan Africa

References

1. 1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization; 2010. pp. 1-359 Available from http://whqlibdoc. who.int/publications/2010/9789241599764_eng.pdf. [Accessed 10 November 2013]
2. 2. OMS. Lignes directrices combinées sur l’utilisation des antirétroviraux pour le traitement et la prévention de l’infection à VIH. Résumé des principales caractéristiques et recomandations. Juin 2013. http://apps.who.int/iris/bitstream/10665/85324/1/WHO_HIV_2013.7_fre.pdf
3. 3. MMW. Atazanavir protects lipid metabolism. New PI with favorable metabolic profile. MMW Fortschr Med 2004; 1: 90.
4. 4. Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. N Microbiol 2007; 2:79-88.
5. 5. Havlir D V, O’Marro S D. Atazanavir: new option for treatment of HIV Infection. Clin Infect Dis 2004; 38:1599–1604
6. 6. De Mendoza C, Garrido C, Corral A, Zahonero N, Soriano V. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. AIDS 2008; 2: 311-313.
7. 7. Rhee S-Y, Taylor J, Fessel WJ, et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother 2010; 10: 4253-4261.
8. 8. Charpentier C, Lambert-Niclot S, Alteri C, et al. Description of the L76V resistance protease mutation in HIV-1 and “Non-B” subtypes. Plos One 2013; 1: e54381.

9. 9. Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1infection: a review. Ther Clin Risk Manag 2008; 5: 1023–1033
10. 10. Mangum E M, Graham K K. Lopinavir-ritonavir: a new protease inhibitor. Pharmacotherapy 2001; 11: 1352-63.
11. 11. Keiser O, Tweya H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23: 1867-1874.
12. 12. Madec Y, Leroy S, Rey-Cuille M-A, Huber F, Calmy A. Persistent difficulties in switching to second-line ART in sub-Saharan Africa -A systematic review and meta-analysis. PLoS One 2013; 8(12): e82724.
13. 13. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646- 655.
14. 14. Foglia E, Bonfanti P, Rizzardini G. Cost-utility analysis of lopinavir-ritonavir versus atazanavir-ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomized trial to real world. Plos One 2013; 2: e57777.
15. 15. Broder MS, Juday T, Uy J, Chang E Y, Bentley TGK. Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy. J Int Aids Soc 2010); 13 (Suppl. 4):P234
16. 16. Laker E, Mambule I, Nalwanga D, Musaazi J, Kiragga A, Parkes-Ratanshi R. Boosted lopinavir versus boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala. J Int Aids Soc 2014; 17 (Suppl 3):19792
17. 17. Gomo ZAR, Hakim JG, Walker SA, et al. Impact of secondline antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study. Aids Research Ther 2014; 11:32.
18. 18. Paton N I, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, and al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371: 234-47.
19. 19. Ferradini L, Ouk V, Segeral O, et al. High efficacy of lopinavir/ r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc 2014; 14:14.
20. 20. Pujades-Rodriguez M, O’Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008; 22; 11:1305-1312.
21. 21. Landman R, Diallo MB, Gueye NF, et al. Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal. AIDS Res Hum Retrovir 2010; 5:519-25.
22. 22. Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009; 1:29-36.
23. 23. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007; 44(11):1484-1492.
24. 24. Soriano V, García-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008; 61(1):200-205.
25. 25. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving. J Infect Dis 2001; 183 (8):1290-1294.
26. 26. Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML. Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS One 2011; 6(7): e21795. doi:10.1371/journal. pone.0021795
27. 27. Balestre E, Eholié SP, Lokossue A, et al. Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. AIDS 2012; 26: 951-957.
28. 28. Tumbarello M, Rabagliati R, de Gaetano Donati K, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy BMC Infect Dis 2004; 4:46.
29. 29. Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation Drug Metab Dispos 2005; 33: 1729-1739
30. 30. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia J Acquir Immune Defic Syndr 2005; 2:174-180.
31. 31. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 8:1381–1386.
32. 32. Floridia M, Ravizza M, Masuelli G, et al. Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. J Antimicrob Chemother 2014; 69(5):1377-1384.
33. 33. Korenblat KM, Berk PD. Hyperbilirubinemia in the setting of antiviral therapy. Clin Gastroenterol Hepatol 2005; 3:303- 310.
34. 34. Sension M, Andrade Neto JL, et al. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 2009; 51:153-162